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Several studies have shown synergism when Cdk inhibitors were combined with organic (e.g., doxorubicin, paclitaxel) 2, 6 and inorganic (e.g., cisplatin, carboplatin) cytotoxic drugs.
7À9
The reported effects inspired the design of metal complexes with biologically active ligands. The first publications have appeared recently and include Fe, Cu, and Pt complexes with Cdk inhibitors derived from 6-benzylaminopurine, 10À13 metalbased indolo- [3,2-d] benzazepines (paullones; Ga, Cu, Ru, and Os), 14À19 and indolo-[3,2-c]quinolines (Ru, Os). 20 Another class of compounds potentially suitable for targeted metal-based chemotherapy is that of 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines. These have been documented recently as potent Cdk1 inhibitors with antiproliferative activity in HeLa (cervical carcinoma), HCT116 (colon carcinoma), and A375 (melanoma) human cancer cell lines. 21À23 Comparison of Cdk1 inhibitory activity with the inhibiting activity in four other protein kinases (VEGF-R2, HER2, Aurora-A, and RET) revealed selectivity for Cdk1. Structural modifications consisting of a replacement of both bicyclic rings in 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines by monocycles while retaining the imidazolyl pyrazole core have been proposed in order to obtain inhibitors with improved pharmacokinetic and solubility properties. 24À26 The most promising were suggested to be 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines (see Chart 1) . The inspection of substitution patterns on the benzimidazole moiety and structureÀactivity relationships revealed that a methoxymethyl group in position 7b (4b 0 ) is favorable for Cdk1 inhibiting potency. The role of the pyrazole NH group is also of note, since its methylation led to a significant reduction of Cdk1 activity. The effect of various heteroaryl groups in position 5a was also remarkable for the development of more-effective Cdk inhibitors and antiproliferative agents.
Our previous experience with metal-based indolo- [3,2-d] benzazepines prompted the use of the half-sandwich metal-arene moiety as a suitable scaffold to which 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4- Cl(η 6 -p-cymene)(L)]Cl, where M = Ru (11a, 12a, 13a) or Os (11b, 12b, 13b) and L = 3-(1H-benzimidazol-2-yl)-1H-pyrazolo- [3,4-b] pyridines (L1ÀL3) have been synthesized. The latter are known as potential cyclin-dependent kinase (Cdk) inhibitors. All compounds have been comprehensively characterized by elemental analysis, one-and two-dimensional NMR spectroscopy, UVÀvis spectroscopy, ESI mass spectrometry, and X-ray crystallography (11b and 12b). The multistep synthesis of 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines (L1ÀL3), which was reported by other researchers, has been modified by us essentially (e.g., the synthesis of 5-bromo-1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid (3) via 5-bromo-3-methyl-1H-pyrazolo [3,4-b] pyridine (2) ; the synthesis of 1-methoxymethyl-2,3-diaminobenzene (5) by avoiding the use of unstable 2,3-diaminobenzyl alcohol; and the activation of 1H-pyrazolo [3,4-b] pyridine-3-carboxylic acids (1, 3) through the use of an inexpensive coupling reagent, N,N 0 -carbonyldiimidazole (CDI)). Stabilization of the 7b tautomer of methoxymethyl-substituted L3 by coordination to a metal(II) center, as well as the NMR spectroscopic characterization of two tautomers 7b-L3 and 4b
0 -L3 in a metal-free state are described. StructureÀactivity relationships with regard to cytotoxicity and cell cycle effects in human cancer cells, as well as Cdk inhibitory activity, are also reported.
Inorganic Chemistry ARTICLE promising anticancer activity and are the focus of attention for several groups. 27À32 These compounds have shown activity toward classic (DNA) and nonclassic (e.g., Cdks) targets in anticancer chemotherapy.
Herein, we report (i) the modified synthetic approach to 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4- 1H-Pyrazolo [3,4-b] pyridine-3-carboxylic acid (1) was obtained via the oxidation of 3-methyl-1H-pyrazolo [3,4-b] pyridine by KMnO 4 in the presence of a base, 35 followed by acidification with 37% HCl. 2-Amino-3-nitrobenzyl alcohol was obtained as reported in the literature. 36 1, 2-Diaminobenzene and dry dimethylformamide (DMF) were purchased from Acros Organics. Solvents [toluene, ethanol (EtOH), tetrahydrofuran (THF), diethyl ether (Et 2 O)] were dried using standard procedures. -p-cymene)] 2 were synthesized as described previously.
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Synthesis of Ligands. 5-Bromo-3-methyl-1H-pyrazolo [3,4-b] pyridine (2). 3-Methyl-1H-pyrazolo [3,4-b] pyridine (10.9 g, 0.08 mol) and anhydrous sodium acetate (10.21 g, 0.13 mol) were suspended in glacial acetic acid (42 mL). Bromine (20.42 g, 0.13 mol) was added, and the resulting mixture was stirred at room temperature for 2À2.5 h and then at 110À115°C for 2.5À3 h. Afterward, water (300À350 mL) was added and the mixture was stirred at room temperature. The formed light yellow precipitate was filtered off and dried in vacuo at 40À50°C. Yield: 17 g. The raw product was used without further purification in the next step. Purification by column chromatography afforded a white powder (SiO 2 , EtOAc, R f = 0.79; 12.5 g, 72.6% yield). M r (C 7 Figure S1 in the Supporting Information).
5-Bromo-1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid (3). To sodium hydroxide (9.54 g, 0.24 mol) in water (150 mL) was added the raw product 2 (7.1 g, 0.03 mol). After a dropwise addition of KMnO 4 (16.98 g, 0.11 mol) in water (300 mL) at 100°C over 2 h, the reaction mixture was further heated for 1 h. MnO 2 was filtered off from the hot reaction mixture and washed with hot water. The filtrates were combined, the water was evaporated to ca. 400 mL, and the yellow solution was acidified to pH ∼2, using concentrated HCl. The yellow precipitate was filtered off and dried in vacuo at 60°C. Yield: 2.28 g. The crude hydrochloride of 3 was used without further purification in the next step. M r (C 7 1-Methoxymethyl-2-amino-3-nitrobenzene (4). NaH (1.75 g, 0.07 mol) was suspended in dry THF (200 mL). A solution of 2-amino-3-nitrobenzyl alcohol (5.23 g, 0.03 mol) in dry THF (100 mL) was added dropwise at 0°C and the mixture was stirred at the same temperature for 15 min. After a dropwise addition of MeI (11.5 g, 0.08 mol), stirring was continued at room Inorganic Chemistry ARTICLE temperature for 3 h. A saturated aqueous solution of NaHCO 3 (300 mL) and MeOH (300 mL) then were added. The mixture was filtered, and the white precipitate was washed with EtOAc. The filtrates were combined, and organic solvents were evaporated under reduced pressure. The remaining aqueous solution was extracted with EtOAc (2 Â 300 mL). The organic phase was dried over Na 2 SO 4 , filtered, and evaporated to yield a red oil (4.85 g). The raw product was purified by column chromatography (SiO 2 , EtOAc, or EtOAc/hexane 1/1, first fraction, a red-orange oil crystallized to form a red solid at 4°C; yield: 3.68 g, 65%). M r (C 8 1-Methoxymethyl-2,3-diaminobenzene (5) . A mixture of 4 (1.4 g, 0.008 mol) and 10% Pd/C (0.18 g) in dry EtOH (55 mL) was stirred under hydrogen atmosphere at room temperature for 18À24 h. The catalyst was removed by filtration through GF-3-filter under argon and washed with dry EtOH (50À70 mL). The filtrate was evaporated in vacuo to give a light-orange solid (1.17 g, 100% yield), which was used immediately in the next step. M r (C 8 (1H-Imidazol-1-yl)(1H-pyrazolo [3,4-b] pyridin-3-yl)methanone (6) . N,N 0 -Carbonyldiimidazole (CDI, 4.16 g, 0.026 mol) was added in small portions to 1 (2.34 g) in dry DMF (12 mL). The mixture was stirred at room temperature for 20À24 h. Water (5 mL) then was added and the suspension was stirred until all CO 2 was ceased. The white precipitate was filtered off, washed with water (3À5 mL), and dried in a sublimator in vacuo at 60°C, to remove the imidazole as a contaminant. Yield: 1.13 g; 25À29%, based on 3-methyl-1H-pyrazolo [3,4-b] pyridine. M r (C 10 (5-Bromo-1H-pyrazolo [3,4-b] pyridin-3-yl)(1H-imidazol-1-yl)methanone (7) . N,N 0 -Carbonyldiimidazole (CDI, 16.2 g, 0.1 mol) was added in small portions to crude 3 (11.58 g) in dry DMF (70 mL). The mixture was stirred at room temperature for 20À24 h. Water (10 mL) then was added and the suspension was stirred until all CO 2 was ceased. The white precipitate was filtered off, washed with water (10À15 mL), and dried in a sublimator in vacuo at 60°C, to remove the imidazole as a contaminant. Yield: 7.27 g, 13À16%, based on 3-methyl-1H-pyrazolo [3,4- (8) . The solution of 1,2-diaminobenzene (0.5 g, 4.67 mmol) in dry DMF (2 mL) was added to the suspension of 6 (0.94 g, 4.41 mmol) in dry DMF (13 mL), and this reaction mixture was heated under argon at 85°C for 5 h. DMF then was evaporated in vacuo at 50°C and water (10À12 mL) was added. The light-yellow precipitate was filtered off and dried in vacuo at 50°C. Yield: 0.86 g. The raw product was used without purification in the next step. M r - (C 13 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridine (11, L1). The raw product 8 (0.86 g) was heated in a glacial acetic acid (10 mL) at 125°C for 2.5 h. The solvent was evaporated under reduced pressure and the residue was dried in vacuo at 50°C, then resuspended in CH 2 Cl 2 /MeOH (4/1, 25 mL), filtered off, and dried in vacuo to give L1 as a white powder (0.4 g). The filtrate was evaporated and the residue was purified by column chromatography (SiO 2 , EtOAc, R f = 0.58) to give an additional amount of L1 (0.22 g). Yield: 0.62 g, ∼60% based on 6. M r (C 13 (C 8a ), 150.22 (C 6a ), 146.99 (C 2b ), 144.34 (C 8b or C 9b ), 136.06 (C 3a ), 134.68 (C 8b or C 9b ), 131.82 (C 4a ), 123.35 (C 5b or C 6b ), 122.11 (C 5b or C 6b ), 119.44 (C 4b or C 7b ), 118.65 (C 5a ), 113.33 (C 9a ), 112.01 (C 4b 3-(1H-Benzimidazol-2-yl)-5-bromo-1H-pyrazolo [3,4-b] pyridine (12, L2) . The raw product 9 (2.2 g) was heated in a glacial acetic acid (30 mL) at 125°C for 2 h. The solvent was evaporated under reduced pressure, and the residue was dried in vacuo at 50°C, then resuspended in CH 2 Cl 2 /MeOH (7/1, 50 mL), filtered off and dried in vacuo to give L2 as a white powder (1.15 g). The filtrate was evaporated and the residue was purified by column chromatography (SiO 2 , EtOAc/hexane 2/1, R f = 0.6) to give an additional amount of the product (0.27 g). Yield: 1.42 g, ∼58% based on 7. M r -(C 13 (C 8a ), 150.66 (C 6a ), 146.42 (C 2b ), 144.24 (C 8b or C 9b ), 135.61 (C 3a ), 134.67 (C 8b or C 9b ), 133.35 (C 4a ), 123.54 (C 5b or C 6b ), 122.27 (C 5b or C 6b ), 119.55 (C 4b or C 7b ), 114.87 (C 5a or C 9a ), 113.49 (C 5a or C 9a ), 112.09 (C 4b or C 7b ) ppm. 15 N NMR (50.70 MHz, DMSO-d 6 ): δ 167.5 (N 1a ), 121.3 (N 1b ) ppm.
5-Bromo-3-(4-methoxymethyl-1H-benzimidazol-2-yl)-1H-pyrazolo-[3,4-b]pyridine (13, L3). The raw product 10 (2.3 g) was heated in a glacial acetic acid (40 mL) at 125°C for 2 h. The solvent was evaporated under reduced pressure, and the residue dried in vacuo at 50°C. After washing with CH 2 Cl 2 (30 mL), CH 2 Cl 2 /MeOH (2/1, 5À7 mL) the gray product was purified by column chromatography (SiO 2 , EtOAc, R f = 0.68) to give a white powder (0.9 g). The filtrates were evaporated and the remaining solid was purified by column chromatography to give an additional amount of the product (0.3 g). Yield: 1.2 g, 47%, based on 7. M r (C 15 (C 6a ), 146.52 (C 2b ), 141.37 (C 9b ), 134.70 (C 8b ), 134.64 (C 3a ), 131.48 (C 4a ), 125.39 (C 5b or C 6b ), 124.92 (C 5b or C 6b ), 119.56 (C 5a ), 117.85 (C 4b ), 113.96 (C 7b ), 111.54 (C 9a ), 103.96 (C 4c ), 103.74 (C 1c ), 84.44 (C 2c or C 6c ), 83.73 (C 2c or C 6c ), 82.15 (C 3c or C 5c ), 80.84 (C 3c or C 5c ), 31.12 (C 7c ( (C 8a ), 148.91 (C 2b ), 147.42 (C 6a ), 140.49 (C 9b ), 135.15 (C 3a ), 134.25 (C 8b ), 132.07 (C 4a ), 125.47 (C 5b or C 6b ), 124.81 (C 5b or C 6b ), 118.48 (C 5a ), 116.89 (C 4b ), 112.98 (C 7b ), 112.92 (C 9a ), 97.71 (C 4c ), 94.88 (C 1c ), 76.44 (C 2c or C 6c ), 74.99 (C 2c or C 6c ), 71.93 (C 3c or C 5c ), 70.44 (C 2c or C 6c ), 31.37 (C 7c ), 21.35 (C 8c or C 9c ), 21 .09 (C 8c or C 9c ), 17.84 (C 10c ) ppm. Crystals of 11b 3 4H 2 O suitable for XRD study have been obtained from a solution of 11b in ethanol.
(η (C 8a ), 151.24 (C 6a ), 146.57 (C 2b ), 141.37 (C 9b ), 134.63 (C 8b ), 133.43 (C 3a ), 131.82 (C 4a Physical Measurements. Elemental analyses (C, H, N, Cl) were performed by the Microanalytical Service of the Institute of Physical Chemistry, University of Vienna. Electrospray ionization mass spectrometry (ESI-MS) was carried out with an Esquire 3000 instrument (Bruker Daltonics, Bremen, Germany), using solutions of compounds in methanol. The expected and measured isotope distributions were compared. UVÀvis spectra were recorded on a Lambda 20 UVÀvis spectrophotometer (PerkinÀElmer), using samples dissolved in methanol (L1ÀL3, 11a, 12a, 13a, 11b, 12b, 13b) and water (11a) over 24 or 48 h, correspondingly. The one-dimensional ( 1 H, 13 C, 15 N) and two-dimensional spectra ( 15 N, 1 H HSQC, 13 C, 1 H HSQC, 13 39 Crystal data, data collection parameters, and structure refinement details are given in Table 1 . The structures were solved by direct methods and refined by full-matrix least-squares techniques. Non-H atoms were refined with anisotropic displacement parameters. H atoms were inserted in calculated positions and refined with a riding model. Refinement of the structure of 12b revealed that the chloride counteranion occupies two statistically disordered positions with site occupation factor (sof) values of 0.57:0.43, whereas, in 13c, the methoxymethylene group was found to be disordered over two positions with sof values of 0.80:0.20. Similarly, the methoxymethylene group of one crystallographically independent complex in 13d 3 CH 3 OH or in both crystallographically independent complexes in 13e 3 0.75CH 3 OH 3 0.25H 2 O is disordered with sof values of 0.35:0.65 and 0.60:0.40, 0.80:0.20, correspondingly. The disorder was resolved with constrained anisotropic displacement parameters and restrained bond distances using EADP and SADI instructions of SHELX97, respectively. Structure solution was achieved with SHELXS-97 and refinement with SHELXL-97, 40 and graphics were produced with ORTEP-3.
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Cell Lines and Culture Conditions. A549 (non-small cell lung carcinoma, human) and SW480 (colon carcinoma, human) cells were kindly provided by Brigitte Marian (Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria). CH1 cells (ovarian cancer, human) were a gift from Lloyd R. Kelland (CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, U.K.). All cell culture media and supplements were purchased from SigmaÀAldrich. Cells were grown in 75-cm 2 culture flasks (Iwaki) in a complete medium (i.e., Minimum Essential Medium supplemented with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, 4 mM L-glutamine, and 1% nonessential amino acids from 100Â stock) as adherent monolayer cultures. Cultures were grown at 37°C under a humidified atmosphere containing 5% CO 2 and 95% air.
Inhibition of Cancer Cell Growth. Antiproliferative activity in vitro was determined by the colorimetric MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Fluka). For this purpose, cells were harvested from culture flasks by the use of trypsin and seeded in complete medium (100 μL/well) into 96-well plates (Iwaki) in densities of 4 Â 10 3 (A549), 1.5 Â 10 3 (CH1), and 2.5 Â 10 3 (SW480) viable cells per well. Cells were allowed for 24 h to settle and resume proliferation. Test compounds were dissolved in DMSO first, appropriately diluted in complete medium, and instantly added to the plates (100 μL/well), where the DMSO content did not exceed 0.4% and 1% for the ligands and complexes, respectively. After exposure for 96 h, the medium was replaced with 100 μL/well RPMI 1640 medium (supplemented with 10% heat-inactivated fetal bovine serum and 4 mM L-glutamine) plus 20 μL/well MTT solution in phosphate-buffered saline (5 mg/mL), followed by incubation for 4 h. Subsequently, the medium/MTT mixture was removed, and the formazan product formed by viable cells was dissolved in DMSO (150 μL/well). Optical densities were measured with a microplate reader (Tecan Spectra Classic) at 550 nm (and a reference wavelength of 690 nm) to yield relative quantities of viable cells as percentages of untreated controls, and 50% inhibitory concentrations (IC 50 ) were interpolated from concentrationÀeffect curves. Calculations are based on at least three independent experiments with triplicates for each concentration level.
Cell Cycle Analyses. To study the effects on the cell cycle of exponentially growing CH1 cells by flow cytometric analysis of their relative DNA content, cells were harvested from culture flasks, seeded in complete medium into 90-mm Petri dishes (1 Â 10 6 cells/dish) and, after recovery for 24 h, exposed to various concentrations of the test compounds for 24 h. For this purpose, test compounds were diluted from DMSO stocks with complete medium (see above) such that the effective DMSO content did not exceed 0.5%. After exposure, treated and control cells were collected by scratching, washed with PBS, and stained with 5 μg/mL propidium iodide overnight. Their fluorescence was measured with a FACS Calibur instrument (Becton Dickinson), and the obtained histograms were analyzed with Cell Quest Pro software (Becton Dickinson). 
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At least two independent experiments were performed for each setting, and 2.5 or 3.0 Â 10 4 cells were measured per sample.
Kinase Assay. The Cdk-inhibitory capacities of test compounds were studied by a radiochemical assay using recombinant Cdk1/cyclin B and Cdk2/cyclin E isolated from Sf21 insect cells and histone H1 as the substrate for phosphorylation, as described by Marko et al. 42 Briefly, MOPS-buffered assay mixtures containing the test compound (with a maximum of 1% DMSO), the respective kinase/cyclin complex, histone H1, and 0.4 μCi (γ-32 P)ATP per sample were incubated for 10 min at 30°C. Aliquots of the solution were spotted onto phosphocellulose squares, which had been washed three times with 0.75% phosphoric acid, followed by acetone. The dried squares were measured in scintillation vials by β-counting (PerkinÀElmer Tri-Carb 2800TR; Quanta Smart software). Results were obtained in duplicate in at least two independent experiments, and IC 50 values were calculated by interpolation. 35 bromination of 1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid methyl ester in an AcOH/AcONa mixture, 23 and hydrolysis of 5-bromo-1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid methyl ester in the presence of NaOH, followed by acidification with HCl. 23 The overall yield of 5-bromo-1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid (3) was 18%.
We performed the synthesis of 3 in two steps (see Scheme 1, steps v and vi): bromination of 3-methyl-1H-pyrazolo [3,4-b] pyridine in AcOH/AcONa mixture and oxidation of crude 5-bromo-3-methyl-1H-pyrazolo [3,4-b] pyridine (2) by KMnO 4 in a basic medium, followed by acidification with 37% HCl, with an overall yield of 24À35%. 5-Bromo-3-methyl-1H-pyrazolo- [3,4-b] pyridine (2) is a known compound, the synthesis of which is well-documented.
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For the benzimidazole ring formation, 1,2-diaminobenzene and 1-methoxymethyl-2,3-diaminobenzene have been used. The reported synthesis of 1-methoxymethyl-2,3-diaminobenzene (5) from 2,3-diaminobenzyl alcohol afforded the desired product in 34% yield (see Scheme 2, step i). 23 However, the instability and low yield of diamines, as well as the necessity to purify the desired ether using column chromatography, stimulated the search for a more-convenient procedure that was subsequently proposed: etherification of 2-amino-3-nitrobenzyl alcohol, followed by the reduction of 1-methoxymethyl-2-amino-3-nitrobenzene (4) with 10% Pd/C in ethanol under a hydrogen atmosphere afforded 5 in 65À75% yield (see Scheme 2, steps ii and iii).
Patented benzimidazole ring formation by cyclization of the 3-carboxyl group of 5-bromo-1H-pyrazolo [3,4-b] pyridine-3-carboxylic acid (3) with substituted 1,2-diaminobenzenes was realized via amide formation using coupling reagents, followed by treatment with glacial acetic acid.
21 HATU (N,N,N 0 ,N 0 -tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate) was used as a coupling reagent. Scheme 2. Synthesis of 1-Methoxymethyl-2,3-diaminobenzene (5) a a Reagents and conditions: (i) NaH, MeI, dry THF, 0°C, 30 min, room temperature, overnight, chromatographic purification, 34% yield; 23 (ii) NaH, MeI, dry THF, 0°C, 15 min, room temperature, 3 h, chromatographic purification, 65À75% yield; (iii) 10% Pd/C, ethanol, H 2 , room temperature, 18À24 h, 100% yield.
For the synthesis of L1ÀL3, we used N,N 0 -carbonyldiimidazole (CDI) as an amide-coupling reagent, because it is relatively inexpensive and the side products, carbon dioxide and imidazole, could be easily removed from the reaction mixture.
CDI-mediated amidation of acids 1 and 3 was performed as shown in Scheme 3 (steps i and ii). In the first step, the acylimidazolides 6 and 7 were obtained in dry DMF at room temperature and isolated as white solids. The yields based on 3-methyl-1H-pyrazolo [3,4-b] pyridine are: 25À29% (6) and 13À16% (7). In the second step, monoacylation of phenylenediamines (1,2-diaminobenzene and 1-methoxymethyl-2,3-diaminobenzene (5)) using acyl-imidazolides was performed in DMF at 80À85°C.
Amides 8À10 were used without further purification in ring closure reactions in a glacial acetic acid at 120À125°C and afforded the desired 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]-pyridines: L1 (55À60%), L2 (58À61%), and L3 (44À51%), based on 6 and 7 (see Scheme 3, step iii). The reported synthesis of L3 is a one-pot approach for amide formation using HATU with 57% yield, followed by cyclization under acidic conditions (acetic acid) with 87% yield.
Thus, the ligands L1, L2, and L3 have been prepared in 7, 8, and 11 steps, correspondingly. NMR Evidence of Ligand Coordination. The full assignment of proton, carbon, and nitrogen resonances for L1ÀL3, 11a, 11b, 12a, 12b, 13a, and 13b is quoted in Tables S1ÀS3 in the  Supporting Information. 3-(1H-Benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines with an unsubstituted benzimidazole moiety (L1, L2) display one set of signals. L1 is characterized by three doublets of doublets for H 4a , H 5a , H 6a (8.85, 7.39, 8.66 ppm, correspondingly) of pyrazolopyridine moiety, two doublets for H 4b , H 7b (7.54 and 7.75 ppm), the overlapped H 5b , H 6b proton signals in one multiplet (7.24 ppm) for a benzimidazole moiety and two singlet resonances for H 1a and H 1b (for atom numbering, see Chart 1). The substitution of H 5a by bromine (L2) results in reduced multiplicity for the H 4a and H 6a signals (two doublets at 8.99 and 8.75 ppm), whereas the benzimidazole moiety spectrum remains almost unchanged. Two singlets were attributed to NH protons and related to pyrazolopyridine (H 1a , at 14.19 (L1), 14.43 (L2) ppm) and benzimidazole (H 1b , at 13.11 (L1), 13.19 (L2) ppm) moieties.
NMR spectra for 11a, 11b, 12a, and 12b, where L1 and L2 coordinate as bidentate ligands via N 2a and N 3b with the formation of a stable five-membered chelate cycle, show one set of signals. There was no evidence for monodentate or tridentate coordination of ligands with the formation of dinuclear or polynuclear complexes.
Coordination of L1 and L2 to ruthenium(II) made it possible to assign the two doublets to proton resonances of H 4b and H 7b of the benzimidazole moiety. In the 1 H, 1 H ROESY plots, one of them has cross-peaks with a CH cymene ring and the nearest to them is H 4b (e.g., at 8.11 (11a), 8.06 (12a) ppm). A singlet at 14.91 (11a), 14.34 (12a) ppm was assigned to NH proton and showed no couplings with other atoms. The nitrogen resonance shift at 128.7 (11a), 127.3 (12a) ppm is closer to the benzimidazole NH chemical shift in metal-free ligands (121.3 (L1, L2) ppm) and, therefore, was assigned as N 1b (see Table S3 in the Supporting Information). The H 1b resonance shows a significant shift by 1.8 and 1.15 ppm for 11a and 12a, respectively, upon ligand coordination (L1 and L2) to the metal(II)-arene moiety. Inorganic Chemistry
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The nearest to the metal binding site pyrazolopyridine proton H 1a was not detected for 11a, 11b, 12a, and 12b, and the proton resonance of H 1b was also not seen for 11b or 12b. L3 displays two sets of signals originated from 7b-L3 and 4b 0 -L3 tautomers (see Chart 1) . Table S1 in the Supporting Information).
According to the 1 H, 1 H ROESY plot, one of the CH 2 groups at 4.80 ppm couples with the NH proton at 13.25 ppm, indicating their attribution to the 7b-L3 tautomer, whereas another NH proton at 13.22 ppm gives a cross-peak with H 7b 0 at 7.47 ppm and belongs to 4b 0 -L3 tautomer (Figure 1 The binding site in 4b 0 -L3 tautomer is sterically shielded by a methoxymethyl group. Consistent with this NMR spectra display, only one set of signals is shown for 13a and 13b with the coordination of the 7b-L3 tautomer to ruthenium(II) and osmium(II) via N 2a and N 3b (see Scheme 4) .
The preference for coordination of the 7b-L3 tautomer is also confirmed by 1 H, 1 H ROESY plots: H 4b (7.99 (13a), 7.91 (13b) ppm) has couplings with CH protons of cymene ring. The crosspeak between H 10b at 4.88 ppm (13a) and NH at 13.88 ppm -(13a) enabled the assignment of this singlet to a benzimidazole moiety (H 1b ). In addition, the chemical shifts for the C atoms of the benzimidazole moiety (C 4b , C 7b , C 5b , C 6b ) of the coordinated ligand and metal-free 7b-L3 tautomer are very similar (see Table S2 in the Supporting Information). The nitrogen resonance at 122.9 ppm (13a) compares well to the benzimidazole NH chemical shift in metal-free L3 at 121.4 ppm. As for 11a, 11b, 12a, and 12b, the nearest to the coordination place pyrazolopyridine proton H 1a resonance was not detected.
According to the 1 H, 1 H ROESY plots of 11a, 12a, 13a, and 13b only CH cymene ring protons have couplings with the nearest H 4b benzene ring proton, suggesting that the isopropyl or methyl groups are further away from the H 4b proton.
Crystal Structures. Figure S2 in the Supporting Information, and Figures 3À6, respectively. All complexes have a typical "three-legged piano-stool" geometry of ruthenium(II) and osmium(II) arene complexes, with an η 6 π-bound p-cymene ring forming the seat and three other donor atoms (two nitrogens N1 and .7°] (overall charge zero) with atom N4 as a proton donor to one of the four co-crystallized water molecules N4ÀH 3 3 3 O3, as occurs in 11b 3 4H 2 O (see Figure 2) .
In 13c, the ligand was found to be deprotonated at N2, acting as a proton acceptor in the intermolecular hydrogen bonding interaction N2 3 3 3 HÀN4 i (i denotes symmetry transformations x, Ày + 1.5, z + 0.5) used to generate equivalent atoms) [N2 3 3 3 N4 Antiproliferative Activity. Ligands L1ÀL3, as well as the corresponding ruthenium(II) (11aÀ13a) and osmium(II) (11bÀ13b) arene complexes, were studied with regard to their capacity of inhibiting cell growth in vitro in the human cancer cell lines CH1 (ovarian carcinoma), SW480 (colon carcinoma), and A549 (non-small cell lung cancer), yielding the IC 50 values listed in Table 2 . All compounds show the strongest effect in the generally chemosensitive CH1 cells, whereas the more chemoresistant A549 cells are also less affected by the compounds investigated here. The antiproliferative activity of the metal-free ligands decreases in the rank order L3 > L2 > L1, indicating that bromination (L2, L3) and, even more so, the double substitution (bromination and an additional replacement of H by a methoxymethyl group (L3)) are advantageous, with regard to activity. These structureÀactivity relationships are also reflected in the rank orders of the corresponding ruthenium and osmium complexes for the ruthenium complexes, 13a > 12a > 11a, and for the osmium complexes, 13b > 12b > 11b.
However, the IC 50 values are shifted to higher concentrations (see Figure 7) . The differences between the ruthenium and osmium analogues are mostly small (IC 50 values differ only up to a factor of 2.4), with the osmium complexes being at least as active as their ruthenium counterparts.
Cell Cycle Effects. Since 3-(1H-benzimidazol-2-yl)-1H-pyrazolo- [3,4-b] pyridines have been reported to be potent Cdk inhibitors, we expected the investigated ligands and complexes to induce cell cycle perturbations. To confirm this assumption in a sensitive cell line, exponentially growing CH1 cells were treated with the compounds for 24 h, stained with propidium iodide, and analyzed for their DNA content by fluorescence-activated cell sorting (FACS) . Surprisingly, the metal-free ligands L1ÀL3 turned out to exert only modest effects on cell cycle distribution, with a slight increase of the G2/M fraction from 32% in the untreated control to 53% by 20 μM L2 as the strongest effect observed in this setting (higher concentrations of this compound led to disintegration of cells already after 24 h). However, the less cytotoxic ruthenium complexes 12a and 13a, both bearing substituted ligands (L2 and L3 correspondingly), cause a more pronounced G2/M phase arrest, as reflected by an increase of this cell fraction to 65% at 80 μM and 59% at 40 μM, respectively, and a concomitant decrease of the G0/G1 fraction to 21% and 24% (compared to 42% in controls), whereas ruthenium complex 11a bearing an unsubstituted ligand L1 is devoid of activity on the cell cycle. On the other hand, the osmium complexes do not generally show stronger effects on the cell cycle than the metal-free ligands, perhaps with the exception of 13b, which induces an increase of the G2/M fraction up to 53% at 80 μM, accompanied by a decline of the G0/G1 fraction to 31% (see Figure 8) .
Cdk-Inhibitory Activity. Although the lack of generally pronounced cell cycle effects does not argue for a strong role of Cdk inhibition in the mechanism of action of the investigated compounds, inhibitory potencies were studied in cell-free experiments with two recombinant Cdk/cyclin complexes, by means of the histone H1 kinase assay. Results reveal that all compounds are capable of inhibiting kinase activities in a concentrationdependent manner, being more effective on Cdk2/cyclin E than on Cdk1/cyclin B (see Figure 9 ). In contrast to the observed cell cycle effects, but in accordance with antiproliferative activities, Cdk-inhibitory potency of the metal-free ligands is consistently higher than that of the metal complexes. In particular, only L1ÀL3 effectively inhibit Cdk2/cyclin E in low concentrations (1 μM or 10 μM), whereas all complexes require higher concentrations to exert >50% inhibitory effects. As in the MTT assay, differences between the effects of corresponding ruthenium and osmium complexes are minor, compared to the differences from those of the metal-free ligands.
' CONCLUSION
The known multistep synthesis of 3-(1H-benzimidazol-2-yl)-1H-pyrazolo [3,4-b] pyridines, which we have modified, essentially afforded three organic compounds (L1ÀL3) that possess Cdk-inhibiting properties. These were used as bidentate ligands, and six novel organometallic complexes of the general formula [M II Cl(η 6 -p-cymene)(L)]Cl, where M = Ru (11a, 12a, 13a) or Os (11b, 12b, 13b) and L = L1ÀL3, have been synthesized and comprehensively characterized using spectroscopic and X-ray diffraction methods. Complexation of L1ÀL3 with ruthenium or osmium yielded compounds with increased solubility in the biological medium, yet lowered antiproliferative activity in human cancer cell lines. Modulation of biological activities by substitution at the ligands can be accomplished in the metal-free molecules and their metal complexes in a similar way. The known Cdk-inhibitory activity of the ligands could be confirmed in cell- 
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ARTICLE free experiments, in particular in Cdk2/cyclin E, and their stronger effects on Cdk activity parallel their higher capacity of inhibiting cancer cell growth in vitro, compared to their metal complexes. Nevertheless, the lack of pronounced effects on the cell cycle of chemosensitive ovarian cancer cells argues against a major role for inhibition of cell growth, at least in this setting.
' ASSOCIATED CONTENT b S Supporting Information. Assigned NMR (
